Supernus's CNS Portfolio Expansion Masking the Real Question About Core ADHD Economics

Supernus Pharmaceuticals (SUPN) reports first-quarter 2026 earnings after market close on May 5, 2026, with investors focused on whether the company can sustain momentum from its growth products while navigating supply challenges for its newly launched Parkinson's disease treatment. The central question is whether SUPN can deliver on its full-year guidance of $840-870 million in total revenues after resuming new patient initiation for ONAPGO in Q1 2026.

Part 1: Earnings Preview

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, with a portfolio spanning ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine treatments. The company's revenue growth is driven by four key products: Qelbree (ADHD), GOCOVRI (Parkinson's), ZURZUVAE (postpartum depression collaboration), and ONAPGO (Parkinson's hypomobility).

Supernus reports Q1 2026 earnings after market close on May 5, 2026, with analysts expecting EPS of $0.14 on limited coverage. The company most recently reported Q4 2025 earnings of $0.75 per share, which dramatically exceeded the $0.14 estimate by 435.71%. Compared to Q1 2025's result of $0.28, the current estimate of $0.14 represents a 50% year-over-year decline, reflecting the company's transition period following the Sage Therapeutics acquisition and ONAPGO supply constraints.

Three key themes define this earnings story:

ONAPGO Supply Resolution and Commercial Trajectory: The resumption of new patient initiation for ONAPGO in Q1 2026 marks a critical inflection point after supply constraints forced the company to pause enrollment following the April 2025 launch. With over 1,800 enrollment forms submitted by more than 540 prescribers through year-end 2025, investors will scrutinize whether the supply resolution translates into accelerating revenue growth toward the company's $45-70 million full-year guidance for the product.

Growth Product Portfolio Performance: The combined revenues of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO reached $521.8 million in 2025, representing 40% year-over-year growth. Investors will watch whether this momentum continues in Q1 2026, particularly for Qelbree (which saw 18% prescription growth in Q4 2025) and ZURZUVAE (which posted 187% year-over-year sales growth in Q4 2025 according to partner Biogen's reporting).

Profitability Path and Operating Leverage: With the company guiding to operating earnings of just $0-30 million for full-year 2026 (down from $81.7 million in 2024) due to acquisition-related costs and integration expenses, investors need clarity on when operating leverage will improve. The guidance for adjusted operating earnings of $140-170 million suggests significant non-cash charges, but the path back to sustainable profitability remains a key question.

Analyst commentary ahead of the release emphasizes cautious optimism. The consensus rating has improved to 4.43 (between Buy and Strong Buy) from 4.14 a month ago, with five Strong Buy ratings, two Holds, and zero Sells among the seven analysts covering the stock. The average price target of $62.67 implies 29% upside from current levels, suggesting analysts see value in the company's CNS portfolio despite near-term execution challenges.

Part 2: Historical Earnings Performance

Supernus Pharmaceuticals has demonstrated a strong pattern of exceeding earnings expectations over the past four quarters, though the magnitude of beats has varied considerably. In Q1 2025, the company reported $0.28 versus the $0.26 estimate, a modest 7.69% beat. Q2 2025 delivered a dramatic surprise with $0.78 against a $0.34 estimate, representing a 129.41% beat. Q3 2025 saw $0.46 versus $0.33 expected, a 39.39% beat. Most recently, Q4 2025 produced the largest surprise of the period with $0.75 against a $0.14 estimate, a remarkable 435.71% beat.

The pattern reveals consistent outperformance, with the company beating estimates in all four quarters. However, the wildly varying magnitude of beats—ranging from 7.69% to 435.71%—suggests either conservative analyst modeling or significant quarter-to-quarter volatility in the business. The particularly large beats in Q2 and Q4 2025 coincide with the Sage acquisition integration period and ONAPGO launch dynamics, indicating analysts may have underestimated the company's ability to manage the transition while maintaining profitability.

Heading into Q1 2026, the $0.14 consensus estimate represents a 50% decline from the prior year's Q1 result of $0.28, suggesting analysts are modeling for continued pressure from acquisition-related costs and ONAPGO supply constraints. Given the company's track record of beating estimates and the resumption of ONAPGO patient initiation in Q1, there may be upside potential to the conservative consensus.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Supernus Pharmaceuticals typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around Supernus earnings shows significant volatility, with an average absolute Day +1 move of 8.29% and an average Day +1 range of 12.75%. The most recent Q4 2025 report on February 24, 2026, produced a Day 0 move of +5.15% and a Day +1 move of +5.67%, with the stock trading in an 8.13% range on the day after results. The Q3 2025 report on November 4, 2025, triggered the most dramatic reaction, with a Day +1 decline of -17.35% despite a modest Day 0 gain of +2.33%, suggesting the market's initial optimism gave way to concerns upon deeper analysis of the results.

The pattern reveals that SUPN tends to experience larger moves on Day +1 than Day 0, consistent with after-hours reporting where the full market reaction unfolds the following session. The Q2 2025 report produced a substantial +13.08% Day +1 move, while Q1 2025 saw a -4.59% Day +1 decline. The average Day 0 move of 1.66% and Day 0 range of 4.41% are relatively modest compared to the Day +1 statistics, reinforcing that the primary price discovery occurs in the session following the earnings release. Investors should prepare for potential double-digit percentage swings based on this historical pattern, particularly if results or guidance deviate significantly from expectations.

Part 2.2: Options Market Expected Move

The options market is pricing in a 4.28% expected move for the May 15, 2026 expiration (11 days away), which is notably lower than SUPN's average historical Day +1 move of 8.29% following earnings. This suggests the options market may be underpricing potential volatility, particularly given the stock's recent history of producing double-digit percentage moves after several earnings reports.

Part 3: What Analysts Are Saying

Analyst sentiment on Supernus Pharmaceuticals currently stands at a consensus rating of 4.43 (between Buy and Strong Buy) with an average price target of $62.67, implying approximately 29% upside from the current price of $48.63. The analyst community shows strong conviction, with five Strong Buy ratings, two Hold ratings, and zero Sell ratings among the seven analysts covering the stock. Price target estimates range from a low of $55.00 to a high of $66.00, indicating relatively tight clustering around the bullish case.

Sentiment has improved over the past month, with the consensus rating rising from 4.14 to 4.43. A month ago, the breakdown included five Strong Buys, one Hold, and one Strong Sell, but the Strong Sell rating has since been upgraded to a Hold, reflecting growing confidence in the company's execution. This positive shift coincides with the resumption of ONAPGO patient initiation and continued momentum in the company's growth product portfolio.

The $62.67 average price target represents substantial upside potential and suggests analysts believe the market is undervaluing SUPN's CNS franchise and pipeline. With the stock trading below all analyst price targets and sentiment trending more bullish, the analyst community appears to view the current valuation as an attractive entry point despite near-term profitability pressures from acquisition integration costs.

Part 4: Technical Picture

Supernus Pharmaceuticals enters earnings with a deteriorating technical picture, as the Barchart Technical Opinion has shifted from 40% Buy a month ago to just 8% Sell currently, with the signal also weakening from 8% Buy last week. The stock is trading at $48.63, positioned below most key moving averages including the 10-day ($49.07), 20-day ($49.87), 50-day ($51.05), and 100-day ($50.44), though it remains above the 5-day ($48.34) and 200-day ($47.76) averages. This configuration suggests the stock has been under pressure in the near-to-intermediate term while maintaining longer-term support.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative heading into the earnings release
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate-term trend remains constructive despite recent weakness
• Long-term (Hold): Neutral reading reflects a balanced longer-term technical outlook without strong directional bias

Trend Characteristics: The Minimum strength and Weakest direction readings indicate the current trend environment is fragile and lacks conviction, suggesting the stock is vulnerable to sharp moves in either direction based on earnings results.

The technical setup heading into earnings is cautionary, with the stock trading in a downtrend from its 50-day moving average and showing deteriorating momentum signals across multiple timeframes. The proximity to the 200-day moving average at $47.76 provides a key support level, but a disappointing earnings report could trigger a break below this longer-term anchor. Conversely, strong results could catalyze a reversal back above the 50-day moving average cluster, potentially setting up a technical breakout. The weak trend characteristics suggest investors should expect heightened volatility, consistent with the stock's historical pattern of producing significant post-earnings moves.

Key technical levels to watch include resistance at the 50-day moving average of $51.05 and support at the 200-day moving average of $47.76. The stock is currently trading on the 5-day moving average and above the 200-day, suggesting it's testing near-term support while maintaining longer-term structural integrity. The overall technical setup is cautionary heading into earnings, with deteriorating momentum signals and the stock positioned below most intermediate-term moving averages, leaving it vulnerable to further downside if results disappoint but also positioned for a potential relief rally if the company delivers positive surprises on ONAPGO traction and growth product momentum.